Characteristics and Glycemic Outcomes of T2D Patients (Pts) Titrated to 60 U/day with Insulin Glargine/Lixisenatide Fixed-Ratio Combination (iGlarLixi) vs. Insulin in the LixiLan-L Trial

被引：0
|
作者：
Blonde, Lawrence
Bailey, Timothy S.
Chao, Jason
Dex, Terry
Frias, Juan P.
Meneghini, Luigi F.
Roberts, Michelle
Aroda, Vanita R.
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1107-P
引用
收藏
页码：A294 / A294
页数：1
相关论文
共 50 条
  • [41] Effect of Single Dose of Insulin Glargine/Lixisenatide Fixed-Ratio Combination (IGlarLixi) on Postprandial Glucodynamic Response in Japanese Patients with Type 2 Diabetes Mellitus
    Inoue, Megumi
    Lorenz, Martin
    Muto, Hideya
    Hashimoto, Yasuhiro
    DIABETES, 2018, 67
  • [42] Improved Glucose Control without Increased Hypoglycemia Risk at Any Level of HbA1c Reduction with Insulin Glargine/Lixisenatide Fixed-Ratio Combination (LixiLan) vs. Insulin Glargine Alone Both Added On to Metformin in Type 2 Diabetes (T2DM)
    Rosenstock, Julio
    Guerci, Bruno
    Paranjape, Sachin
    Berria, Rachele
    Souhami, Elisabeth
    Aroda, Vanita
    DIABETES, 2015, 64 : A44 - A45
  • [43] Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis
    Ádám G. Tabák
    John Anderson
    Pablo Aschner
    Minzhi Liu
    Aramesh Saremi
    Peter Stella
    Francisco J. Tinahones
    Carol Wysham
    Juris J. Meier
    Diabetes Therapy, 2020, 11 : 305 - 318
  • [44] Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis
    Tabak, Adam G.
    Anderson, John
    Aschner, Pablo
    Liu, Minzhi
    Saremi, Aramesh
    Stella, Peter
    Tinahones, Francisco J.
    Wysham, Carol
    Meier, Juris J.
    DIABETES THERAPY, 2020, 11 (01) : 305 - 318
  • [45] Real-World Health Outcomes in Patients with T2D Initiating Insulin Glargine 300 U/mL vs. Insulin Glargine 100 U/mL in a Specialist Endocrinology Practice
    Abitbol, Alexander
    Brown, Ruth E.
    Jiandani, Dishay
    Aronson, Ronnie
    DIABETES, 2017, 66 : A272 - A272
  • [46] A reduced risk of hypoglycaemia with insulin degludec vs. insulin glargine U100 in Asian insulin-naive patients with T2D
    Yang, Wenying
    Li, Qiang
    Li, Zhengfang
    Yang, Jin-Kui
    Ye, Shandong
    Hansen, Charlotte
    Xu, Hongfei
    Pan, Changyu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S115 - S115
  • [47] Clinical impact of titratable fixed-ratio combination of insulin glargine/lixisenatide vs each component alone in type 2 diabetes inadequately controlled on oral agents: LixiLan-O trial (NCT02058147).
    Rosenstock, Julio
    Aronson, Ronnie
    Hanefeld, Markolf
    Piatti, Piermarco
    Serusclat, Pierre
    Cheng, Xi
    Zhou, Tianyue
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Grunberger, George
    Davies, Melanie
    PHARMACOTHERAPY, 2016, 36 (12): : E231 - E232
  • [48] Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial
    Watada, Hirotaka
    Takami, Akane
    Spranger, Robert
    Amano, Atsushi
    Hashimoto, Yasuhiro
    Niemoeller, Elisabeth
    DIABETES CARE, 2020, 43 (06) : 1249 - 1257
  • [49] Similar Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin Naive or Experienced Patients with T2D
    Silver, Robert J.
    Asong, Marisse
    Begtrup, Kamilla
    Koefoed, Mette M.
    Heller, Simon R.
    Rosenstock, Julio
    DIABETES, 2021, 70
  • [50] Higher Derived Time-in-Range with IDegLira vs. Insulin Glargine U100 in Patients with T2D
    Philis-Tsimikas, Athena
    Aroda, Vanita R.
    De Block, Christophe
    Billings, Liana K.
    Hachmann-Nielsen, Elise
    Liebl, Andreas
    Sivarathinasami, Ramsathish
    D'Cruz, John M.
    Lingvay, Ildiko
    DIABETES, 2021, 70
12345